Article
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.
Hepatology (Baltimore, Md.) - 1 Jul 2008
Warner Nadia, Locarnini Stephen
Abstract excerpt
UNLABELLED: The hepatitis B virus (HBV) mutation that encodes rtA181T is selected in the viral polymerase during antiviral drug therapy and can also encode a stop codon in the overlapping surface gene at amino acid 172 (sW172*) resulting in truncation of the last 55 amino acids of the C-terminal hydrophobic region of the surface proteins. This mutation is usually detected as a mixed population with wild-type HBV....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.